
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+1
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Companys pipeline leverages its proprietary Durasert technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Duraserts proven intravitreal drug delivery platform has been safely administered to thousands of patients eyes across four U.S. FDA-approved products, including YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in...
Ophthalmology,glaucoma,wetamd,optometry,eye disease,and retinal disease
Eyepoint pharmaceuticals operates in the Biotechnology research industry.
Eyepoint pharmaceuticals's revenue is 11m - 100m
Eyepoint pharmaceuticals has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.